GIM
EWTX icon

Glenmede Investment Management’s Edgewise Therapeutics EWTX Stock Holding History

Glenmede Investment Management’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$181K Sell
11,137
-1,405
-11% -$19.9K ﹤0.01% 1279
2025
Q2 		$164K Buy
+12,542
New +$181K ﹤0.01% 1259

Other funds holding EWTX

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Glenmede Investment Management's EWTX Position: Q3 2025 in Review

Glenmede Investment Management reduced its Edgewise Therapeutics (EWTX) stake by 11% in Q3 2025, selling an estimated $19.9K and leaving 11,137 shares worth $181K. The position accounts for ﹤0.01% of the portfolio, ranked #1279.

Glenmede Investment Management first reported a position in EWTX in Q2 2025 and has held it in 2 quarters since. 173 funds tracked by Wall St. Rank hold EWTX as of Q3 2025.

  • Glenmede Investment Management held 11,137 shares of Edgewise Therapeutics worth $181K as of Q3 2025.
  • Glenmede Investment Management sold 1,405 Edgewise Therapeutics shares in Q3 2025, an estimated $19.9K.
  • Edgewise Therapeutics made up ﹤0.01% of Glenmede Investment Management's portfolio in Q3 2025, its #1279 holding.
  • Glenmede Investment Management first reported a position in Edgewise Therapeutics in Q2 2025 and has held it in 2 quarters since.
  • 173 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q3 2025.

Based on Glenmede Investment Management's 13F filing for Q3 2025, filed 13 Nov 2025.